Literature DB >> 17083763

Remission of rheumatoid arthritis: should we care about definitions?

D Aletaha1, J S Smolen.   

Abstract

A state of remission can be achieved in more and more rheumatoid arthritis (RA) patients. The combination of several RA disease activity measures seems to be important to provide an overall view of disease activity. Remission can be defined by two different approaches: one using a categorical model, requiring criteria for multiple variables to be fulfilled, each with its own threshold value (remission "criteria"); the other using a dimensional model, providing single measures of activity, which allow definition of remission by a single cut point (remission cut points for composite indices). The face validity of remission as defined by composite indices surpasses the one for the "criteria". Likewise, the ones that are not weighted seem to surpass the weighted ones, as can be seen by the significant proportion of patients that continues to have considerable swollen joint counts despite being in Disease Activity Score (DAS)-28 remission. All composite indices seem to perform similarly well as tests for remission using expert judgments as the gold standard.

Entities:  

Mesh:

Year:  2006        PMID: 17083763

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  17 in total

1.  Management of rheumatoid arthritis: what happens and what does not happen in real life.

Authors:  Daniel Aletaha
Journal:  Rheumatol Int       Date:  2015-12-19       Impact factor: 2.631

2.  Optimal use of methotrexate: the advantages of tight control.

Authors:  J W J Bijlsma; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

3.  Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy.

Authors:  Veena K Ranganath; Kambiz Motamedi; Espen A Haavardsholm; Paul Maranian; David Elashoff; Fiona McQueen; Erin L Duffy; Joan M Bathon; Jeffrey R Curtis; Weiling Chen; Larry Moreland; James Louie; Sogol Amjadi; James O'Dell; Stacey S Cofield; E William St Clair; S Louis Bridges; Harold E Paulus
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

Review 4.  Outcome assessments in rheumatoid arthritis.

Authors:  Katarzyna Gilek-Seibert; Kara Prescott; Salahuddin Kazi
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

5.  Inactive disease and remission in childhood-onset systemic lupus erythematosus.

Authors:  Rina Mina; Marisa S Klein-Gitelman; Angelo Ravelli; Michael W Beresford; Tadej Avcin; Graciela Espada; B Anne Eberhard; Laura E Schanberg; Kathleen M O'Neil; Clovis A Silva; Gloria C Higgins; Karen Onel; Nora G Singer; Emily von Scheven; Lisa F Imundo; Shannen Nelson; Edward H Giannini; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

6.  Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.

Authors:  H Singh; V Gupta; S Ray; H Kumar; P Talapatra; M Kaur; S Kumar; S Arya; R Mathur; N Ghangas
Journal:  Clin Rheumatol       Date:  2012-09-15       Impact factor: 2.980

7.  A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release.

Authors:  Katia Varani; Melissa Padovan; Fabrizio Vincenzi; Martina Targa; Francesco Trotta; Marcello Govoni; Pier Andrea Borea
Journal:  Arthritis Res Ther       Date:  2011-12-06       Impact factor: 5.156

Review 8.  Induction of remission in rheumatoid arthritis: criteria and opportunities.

Authors:  Guido Valesini; Manuela Di Franco; Francesca Romana Spinelli; Rossana Scrivo
Journal:  Rheumatol Int       Date:  2008-09-21       Impact factor: 3.580

9.  Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.

Authors:  Michel de Bandt; Bruno Fautrel; Jean Francis Maillefert; Jean Marie Berthelot; Bernard Combe; René-Marc Flipo; Frédéric Lioté; Olivier Meyer; Alain Saraux; Daniel Wendling; Xavier Le Loët; Francis Guillemin
Journal:  Arthritis Res Ther       Date:  2009-10-23       Impact factor: 5.156

10.  Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.

Authors:  H M Schenker; K Tascilar; L Konerth; M Sergeeva; J Prade; S Strobelt; A Kleyer; D Simon; L Mendez; M Hagen; V Schönau; A Hueber; J Roesch; A Dörfler; A Hess; G Schett; J Rech
Journal:  Contemp Clin Trials Commun       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.